title: A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.
abstract: OBJECTIVE
  Interleukin (IL)-12 is a cytokine that stimulates T lymphocytes and natural killer cells to generate a Type 1 T-helper lymphocyte immune response. The primary objective of this study was to determine the safety and immunologic activity of repeated recombinant human IL-12 (rhIL-12) dosing in HIV-infected patients over a broad range of the HIV disease spectrum.
  
  
  METHODS
  A randomized, placebo-controlled, Phase 1 trial design was chosen to control for the effects of HIV disease alone on safety and immunologic measurements.
  
  
  METHODS
  HIV-infected patients on antiretroviral therapy received rhIL-12 or placebo twice weekly for 4 weeks. Subjects were monitored for safety and changes in absolute lymphocyte subset number, serum interferon (IFN)gamma and neopterin levels, plasma HIV RNA level, peripheral blood mononuclear cell (PBMC)-inducible IFNgamma responses to mitogen, and PBMC proliferative responses to phytohemagglutinin, tetanus, Candida, Mycobacterium avium complex, streptokinase, and HIV p24 and gp160 antigens.
  
  
  RESULTS
  rhIL-12 was well tolerated at doses up to 100 ng/kg in subjects enrolled with CD4 cell counts < 50 x 10(6) cells/l and at all doses in subjects with CD4 cell counts of 300 x 10(6)-500 x 10(6) cells/l. rhIL-12 resulted in dose-related increases in serum neopterin (particularly in subjects with baseline CD4 cell counts of 300-500 x 10(6) cells/l) but in no significant changes in other immunologic measurements or plasma HIV RNA levels.
  
  
  CONCLUSIONS
  rhIL-12 dosed twice weekly at < or = 100 ng/kg was well tolerated in HIV-infected patients and resulted in dose-related increases in serum neopterin (possibly reflecting the effect of some degree of IFNgamma induction). However, there was no evidence of improvement in antigen-specific immune response.
authors: Positive Health Program, Department of Medicine, University of California, San Francisco and The Medical Service, San Francisco General Hospital, San Francisco, CA, USA.
authors: Mark A
authors: MA
authors: Jacobson
authors: John
authors: J
authors: Spritzler
authors: Alan
authors: A
authors: Landay
authors: Ellen
authors: E
authors: Chan
authors: David
authors: D
authors: Katzenstein
authors: Barbara
authors: B
authors: Schock
authors: Lawrence
authors: L
authors: Fox
authors: JoanaD'arc
authors: J
authors: Roe
authors: Smriti
authors: S
authors: Kundu
authors: Richard
authors: R
authors: Pollard
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002455:Cell Division; D004311:Double-Blind Method; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D018664:Interleukin-12 / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008214:Lymphocytes / Q000276:immunology; D008875:Middle Aged; D019798:Neopterin / Q000097:blood; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D011994:Recombinant Proteins; D018664:Interleukin-12; D019798:Neopterin; D007371:Interferon-gamma